Shares of Sotera Health (NASDAQ:SHC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $16.08.
Several research firms have recently commented on SHC. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research note on Friday, December 6th. They set a “neutral” rating and a $14.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research report on Thursday, November 21st. Finally, Citigroup upped their price target on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.
View Our Latest Stock Report on SHC
Institutional Investors Weigh In On Sotera Health
Sotera Health Trading Down 0.7 %
Shares of SHC opened at $13.39 on Friday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market cap of $3.79 billion, a price-to-earnings ratio of 53.56 and a beta of 1.92. The stock has a fifty day moving average price of $13.79 and a two-hundred day moving average price of $14.38. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44.
Sotera Health (NASDAQ:SHC – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. During the same period in the prior year, the firm earned $0.18 earnings per share. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. Analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.
About Sotera Health
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Further Reading
- Five stocks we like better than Sotera Health
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 3 Warren Buffett Stocks to Buy Now
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.